tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NVCR Stock Latest News

Novocure Ltd. Reports Q3 2025 Financial Results
Company AnnouncementsNovocure Ltd. Reports Q3 2025 Financial Results
7h ago
NVCR
Novocure price target raised to $42 from $38 at H.C. Wainwright
PremiumThe Fly
Novocure price target raised to $42 from $38 at H.C. Wainwright
20h ago
NVCR
Novocure reports Q3 EPS (33c), consensus (42c)
PremiumThe Fly
Novocure reports Q3 EPS (33c), consensus (42c)
24h ago
NVCR
Novocure reports Q3 EPS (33c), consensus (42c)
PremiumThe Fly
Novocure reports Q3 EPS (33c), consensus (42c)
24h ago
NVCR
NVCR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
NVCR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3d ago
NVCR
NovoCure’s Phase 3 Glioblastoma Study: A Potential Game-Changer in Cancer Treatment
PremiumCompany AnnouncementsNovoCure’s Phase 3 Glioblastoma Study: A Potential Game-Changer in Cancer Treatment
4d ago
NVCR
NovoCure’s LUNAR-2 Study: A New Horizon in Lung Cancer Treatment
Premium
Company Announcements
NovoCure’s LUNAR-2 Study: A New Horizon in Lung Cancer Treatment
4d ago
NVCR
NovoCure’s TIGER Meso Study: A Promising Update for Pleural Mesothelioma Treatment
Premium
Company Announcements
NovoCure’s TIGER Meso Study: A Promising Update for Pleural Mesothelioma Treatment
4d ago
NVCR
NovoCure’s LUNAR-4 Study: A New Horizon in Lung Cancer Treatment
PremiumCompany Announcements
NovoCure’s LUNAR-4 Study: A New Horizon in Lung Cancer Treatment
4d ago
NVCR
NovoCure’s TIGER France Study: A Potential Game-Changer for Glioblastoma Treatment
PremiumCompany Announcements
NovoCure’s TIGER France Study: A Potential Game-Changer for Glioblastoma Treatment
4d ago
NVCR
Novocure price target lowered to $23 from $25 at JPMorgan
PremiumThe Fly
Novocure price target lowered to $23 from $25 at JPMorgan
4d ago
NVCR
Buy Rating for NovoCure: Promising Phase 3 METIS Trial Results and FDA Approval Plans
PremiumRatings
Buy Rating for NovoCure: Promising Phase 3 METIS Trial Results and FDA Approval Plans
1M ago
NVCR
Novocure to present final results from pivotal Phase 3 METIS trial at ASTRO
PremiumThe FlyNovocure to present final results from pivotal Phase 3 METIS trial at ASTRO
1M ago
NVCR
NovoCure Gains Approval for Optune Lua in Japan
Premium
Company Announcements
NovoCure Gains Approval for Optune Lua in Japan
2M ago
8K
NVCR
Novocure announces Japan MHLW approval for Optune Lua
Premium
The Fly
Novocure announces Japan MHLW approval for Optune Lua
2M ago
NVCR
Novocure announces coverage for Tumor Treating Fields therapy in Spain
PremiumThe Fly
Novocure announces coverage for Tumor Treating Fields therapy in Spain
2M ago
NVCR
Novocure submits Tumor Treating Fields therapy premarket approval application
PremiumThe Fly
Novocure submits Tumor Treating Fields therapy premarket approval application
2M ago
NVCR
NovoCure’s Pivotal Study on Optune® for Glioblastoma: A Market Game-Changer?
PremiumCompany Announcements
NovoCure’s Pivotal Study on Optune® for Glioblastoma: A Market Game-Changer?
3M ago
NVCR
Novocure’s Earnings Call: Clinical Successes & Cautious Optimism
PremiumCompany Announcements
Novocure’s Earnings Call: Clinical Successes & Cautious Optimism
3M ago
NVCR
Positive Outlook for NovoCure: Strong Financial Performance and Promising Pipeline Developments
PremiumRatingsPositive Outlook for NovoCure: Strong Financial Performance and Promising Pipeline Developments
3M ago
NVCR
Novocure Ltd. Reports Q2 2025 Financial Results
Premium
Company Announcements
Novocure Ltd. Reports Q2 2025 Financial Results
3M ago
NVCR
Wells Fargo downgrades Novocure after ‘disappointing’ Q2
Premium
The Fly
Wells Fargo downgrades Novocure after ‘disappointing’ Q2
3M ago
NVCR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >